CHEMOTHERAPY OFFSHOOT

In spite of remarkable development in antiemetic therapies, Chemotherapy Induced Nausea and Vomiting (CINV) is still a grieve symptom in children undergoing chemotherapy. Nauseous clinical complications such as dehydration, electrolyte imbalance and physical strain can occur as a result of inadequate control on CINV. Proper antiemetic treatment should be selected by evaluating the emetogenic risk of chemotherapy as a single agent and as a combination therapy. The effect of CINV may become more intense and may impact the patient’s aspect of life, leading to lack of patient consent and interfering with the ability to deliver more intensive chemotherapy regimens. Here, we focus on key principles that inform the background of CINV in paediatric patients, reviewing the risk factors associated with CINV and which aim to evaluate the current practice of antiemetic medication. Nearly all clinical studies for CINV are focused on adult population but we are considering paediatrics as our prime object.

Chemotherapy Induced Nausea and Vomiting (CINV) is a grave symptom in children receiving cancer treatment that even impacts their quality of life. More than 40 percent of children receiving cancer treatment reported nausea and vomiting caused by chemotherapy even when antiemetic medications were used. With the recent approaching antiemetic drugs, the current treatments of CINV have become highly effectual in reducing the adverse effects. In addition, there are emerging patient derived risk factors associated with CINV which should be decoded. The aim of this review is to evaluate the current practice in antiemetic medications for paediatrics undergoing CINV. Contemporary studies have shown espousal of ‘triple therapy’ regimen of antiemetic prophylaxis (5-HT3 antagonist, dexamethasone and neurokinin-1) as a foundation for prevention of CINV in paediatrics.

Pranjul Shrivastava

Assistant Professor

Faculty of Pharmacy

Kalinga University

Naya Raipur

REFERENCE

URL: https://link.springer.com/article/10.1007/s11912-019-0840-0